Nothing Special   »   [go: up one dir, main page]

CL2021003408A1 - Inhibidor de egfr para el tratamiento de cáncer - Google Patents

Inhibidor de egfr para el tratamiento de cáncer

Info

Publication number
CL2021003408A1
CL2021003408A1 CL2021003408A CL2021003408A CL2021003408A1 CL 2021003408 A1 CL2021003408 A1 CL 2021003408A1 CL 2021003408 A CL2021003408 A CL 2021003408A CL 2021003408 A CL2021003408 A CL 2021003408A CL 2021003408 A1 CL2021003408 A1 CL 2021003408A1
Authority
CL
Chile
Prior art keywords
cancer treatment
egfr inhibitor
cancer
ring
treatment
Prior art date
Application number
CL2021003408A
Other languages
English (en)
Inventor
Annick Goergler
Georg Jaeschke
Bernd Kuhn
Sander Ulrike Obst
Antonio Ricci
Daniel Rueher
Sandra Steiner
Cosimo Dolente
David Hewings
Yvonne Alice Nagel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CL2021003408A1 publication Critical patent/CL2021003408A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La solicitud se refiere a un compuesto de fórmula (I) que contiene un anillo tiazol, un anillo indazol y un sistema de anillo 6,7-dihidro-5H-pirrolo[1,2-c]imidazol, a las composiciones farmacéuticas que lo contienen y a su uso médico. Los compuestos se describen como inhibidores alostéricos selectivos de T790M/L858R, T790M/L858R/C797S, L858R, L858R/C797S que contienen mutantes de EGFR y, de este modo, son útiles para el tratamiento de cáncer, en particular, cáncer de pulmón no microcítico.
CL2021003408A 2019-06-21 2021-12-20 Inhibidor de egfr para el tratamiento de cáncer CL2021003408A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21

Publications (1)

Publication Number Publication Date
CL2021003408A1 true CL2021003408A1 (es) 2022-10-14

Family

ID=67139601

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021003408A CL2021003408A1 (es) 2019-06-21 2021-12-20 Inhibidor de egfr para el tratamiento de cáncer

Country Status (29)

Country Link
US (4) US20230054473A1 (es)
EP (4) EP3986897B1 (es)
JP (4) JP7550799B2 (es)
KR (1) KR20220024105A (es)
CN (4) CN113993872B (es)
AR (4) AR119206A1 (es)
AU (1) AU2020295703A1 (es)
BR (1) BR112021025445B1 (es)
CA (1) CA3140485A1 (es)
CL (1) CL2021003408A1 (es)
CO (1) CO2021017173A2 (es)
CR (1) CR20210624A (es)
DK (1) DK3986897T3 (es)
ES (1) ES2961187T3 (es)
FI (1) FI3986897T3 (es)
HR (1) HRP20231276T1 (es)
HU (1) HUE063676T2 (es)
IL (1) IL288522B2 (es)
LT (1) LT3986897T (es)
MA (1) MA56508B1 (es)
MX (1) MX2021015464A (es)
PE (1) PE20220576A1 (es)
PH (1) PH12021553190A1 (es)
PL (1) PL3986897T3 (es)
PT (1) PT3986897T (es)
RS (1) RS64720B1 (es)
SI (1) SI3986897T1 (es)
TW (3) TW202115074A (es)
WO (4) WO2020254572A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020295703A1 (en) 2019-06-21 2022-01-06 F. Hoffmann-La Roche Ag EGFR inhibitor for the treatment of cancer
EP3986566B1 (en) 2019-06-21 2023-08-30 F. Hoffmann-La Roche AG New egfr inhibitors
KR20250009977A (ko) * 2022-05-13 2025-01-20 에프. 호프만-라 로슈 아게 암 치료를 위한 알로스테릭 및 오르토스테릭 egfr 억제제의 조합물
WO2023217923A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag New indazole derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
JP2011525927A (ja) 2008-06-25 2011-09-29 シェーリング コーポレイション 複素環式抗菌剤の合成および使用
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN107108613B (zh) * 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
BR112017024481B1 (pt) 2015-05-14 2020-11-17 The Wistar Institute Of Anatomy And Biology composto inibidor de ebna1, composição farmacêutica compreendendo dito composto e usos terapêuticos do mesmo
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
SG11202011818YA (en) * 2018-06-29 2020-12-30 Hoffmann La Roche Compounds
US20220315577A1 (en) 2019-06-21 2022-10-06 Hoffmann-La Roche Inc. New egfr inhibitors
EP3986566B1 (en) 2019-06-21 2023-08-30 F. Hoffmann-La Roche AG New egfr inhibitors
AU2020295703A1 (en) 2019-06-21 2022-01-06 F. Hoffmann-La Roche Ag EGFR inhibitor for the treatment of cancer

Also Published As

Publication number Publication date
EP3986895B1 (en) 2023-03-15
DK3986897T3 (da) 2023-10-30
AR119210A1 (es) 2021-12-01
JP2022537191A (ja) 2022-08-24
EP3986895A1 (en) 2022-04-27
BR112021025445A2 (pt) 2022-02-01
US20220315593A1 (en) 2022-10-06
EP3986898A1 (en) 2022-04-27
EP3986898B1 (en) 2023-03-15
MA56508B1 (fr) 2023-11-30
CR20210624A (es) 2022-02-14
SI3986897T1 (sl) 2023-12-29
CO2021017173A2 (es) 2022-01-17
US20230054473A1 (en) 2023-02-23
JP7530391B2 (ja) 2024-08-07
EP3986897A1 (en) 2022-04-27
PH12021553190A1 (en) 2022-11-07
HRP20231276T1 (hr) 2024-02-02
US20220315592A1 (en) 2022-10-06
JP2022537769A (ja) 2022-08-29
JP2022538055A (ja) 2022-08-31
CN113993872B (zh) 2024-09-24
PT3986897T (pt) 2023-10-23
TW202115072A (zh) 2021-04-16
CN113966335A (zh) 2022-01-21
EP3986896A1 (en) 2022-04-27
WO2020254565A1 (en) 2020-12-24
TW202115071A (zh) 2021-04-16
WO2020254568A1 (en) 2020-12-24
HUE063676T2 (hu) 2024-01-28
AR119206A1 (es) 2021-12-01
IL288522B1 (en) 2024-10-01
EP3986897B1 (en) 2023-08-30
KR20220024105A (ko) 2022-03-03
JP2022538403A (ja) 2022-09-02
IL288522A (en) 2022-01-01
JP7550798B2 (ja) 2024-09-13
CN113993873A (zh) 2022-01-28
WO2020254562A1 (en) 2020-12-24
PL3986897T3 (pl) 2024-01-22
CN113993872A (zh) 2022-01-28
IL288522B2 (en) 2025-02-01
CN113966335B (zh) 2024-08-02
PE20220576A1 (es) 2022-04-20
JP7550799B2 (ja) 2024-09-13
CN113993873B (zh) 2024-08-02
MA56508A (fr) 2022-04-27
AU2020295703A1 (en) 2022-01-06
AR119209A1 (es) 2021-12-01
AR119208A1 (es) 2021-12-01
RS64720B1 (sr) 2023-11-30
TW202115074A (zh) 2021-04-16
WO2020254572A1 (en) 2020-12-24
ES2961187T3 (es) 2024-03-08
CN114008049B (zh) 2024-07-05
JP7550800B2 (ja) 2024-09-13
MX2021015464A (es) 2022-01-24
CN114008049A (zh) 2022-02-01
US20220135571A1 (en) 2022-05-05
TW202115053A (zh) 2021-04-16
CA3140485A1 (en) 2020-12-24
FI3986897T3 (fi) 2023-10-20
LT3986897T (lt) 2023-11-10
BR112021025445B1 (pt) 2024-02-27
EP3986896B1 (en) 2023-03-15

Similar Documents

Publication Publication Date Title
CL2021003408A1 (es) Inhibidor de egfr para el tratamiento de cáncer
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
PE20190656A1 (es) Compuestos de tiazolo-piridina sustituida como inhibidores de malt1
CO2021007230A2 (es) Inhibidores de cinasa 7 dependiente de ciclina (cdk7)
NZ766835A (en) Pharmaceutical compounds
CL2017002207A1 (es) Inhibidores del factor beta de crecimiento de transformación (tgf-beta)
GEP20217242B (en) Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CL2019003669A1 (es) Inhibidores de quinasa alk2 que contienen imidazol.
AR122351A1 (es) Derivados de metilquinazolinona como inhibidores de braf
AR041184A1 (es) Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso
ECSP034642A (es) Derivados de tetralona como agentes antitumorales
BR112017016487A2 (pt) 7-benzil-4- (2-metilbenzil) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirrido [3,4-e] pirimidin-5 (1h) -ona, análogos desta, e sais do mesmo e métodos para sua utilização na terapia
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
CR7716A (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
AR115663A1 (es) Compuestos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CO2022000749A2 (es) Inhibidores de monoacilglicerol lipasa (magl) heterocíclicos
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
EA201591904A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ N-(2,3-ДИГИДРО-1H-ПИРРОЛО[2,3-b]ПИРИДИН-5-ИЛ)-4-ХИНАЗОЛИНАМИНА И N-(2,3-ДИГИДРО-1H-ИНДОЛ-5-ИЛ)-4-ХИНАЗОЛИНАМИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PERK
MX2024009404A (es) Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias.
CL2023002632A1 (es) Derivados de 3h,4h-tieno [2,3-d]pirimidin-4-ona como inhibidores de trpa1
DOP2024000254A (es) Macrociclos de indazol y su uso
CO2024012743A2 (es) Derivados de 6-oxodecahidropirrolo[1,2-a][1,5]diazocina y 6-oxodecahidro-4h-pirrolo[2,1-d][1,5]tiazocina como moduladores de stat3 y stat6 para el tratamiento de cáncer y condiciones inflamatorias
DOP2023000088A (es) Derivados de pirazol como inhibidores de la ret-cinasa
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.